Use of mometasone furoate for treating airway passage and lung diseases
Patent 6057307 Issued on May 2, 2000. Estimated Expiration Date: 
March 1, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
March 1, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References3,20-Dioxo-1,4-pregnadiene-17-ol 17-aromatic heterocycle carboxylates Patent #: 4472393 Inventors
AssigneeApplicationNo. 259721 filed on 03/01/1999US Classes:514/169, Cyclopentanohydrophenanthrene ring system DOAI514/172, Hetero ring containing514/176, Nitrogen containing hetero ring514/182, Oxygen single bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system514/826, ASTHMA514/958FOR SMOKING OR INHALINGExaminersPrimary: Clardy, S. MarkAttorney, Agent or FirmForeign Patent References
International ClassesA61K 031/56A61K 031/58 AbstractThe administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.Other References
| |
